Interestingly, lenalidomide treatment of MM cells determined a deregulation of CK1α expression, in a time- and dose-dependent manner, in a mechanism similar to that observed in other cell types [70]. This evidence concerns the gene CSNK1A1 and Miyoshi myopathy.